checkAd

    Optimi Health Achieves Milestone  137  0 Kommentare Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API) - Seite 2

    Optimi’s in-house MDMA manufacturing and encapsulation expertise can viewed on the Company’s YouTube page by clicking here.

    4th Annual Psychedelic Therapeutics and Drug Development Conference:

    Optimi’s world-class psychedelic manufacturing operations will be on full display this May at the 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston (May 23-24). Bill Ciprick will deliver a presentation on Thursday, May 23, 2024, at 10:40 a.m. EST. His session, titled “Manufacturing the Future of GMP Psychedelics: What Researchers, Clinicians, and Drug Developers Need to Know,” promises to provide invaluable insights into the evolving landscape of Good Manufacturing Practice (GMP) psychedelic drugs.

    For media inquiries, please contact Michael Kydd:

    michaelk@optimihealth.ca 
    902.880.6121

    For investor inquiries, please contact:
    investors@optimihealth.ca 

    www.optimihealth.ca 

    ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN):

    Optimi Health Corp. is a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug candidates throughout the world. Optimi’s products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.

    FORWARDLOOKING STATEMENTS:

    This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. forward-looking statements made in this news release include the proposed use of the proceeds of the Offering. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

    Seite 2 von 3


    Aktuelle Themen


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Optimi Health Achieves Milestone Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API) - Seite 2 Three batches tested and validated by third-party laboratoryVANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical …

    Schreibe Deinen Kommentar

    Disclaimer